RecallRadar

FDA Drug recall D-0096-2024

Oxybutynin Chloride Extended-Release Tablet USP, 5 mg, 100 count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Baddi, India

On 2023-11-15 the FDA classified a Class II recall of Oxybutynin Chloride Extended-Release Tablet USP, 5 mg, 100 count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Baddi, India by Zydus Pharmaceuticals Usa, citing failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0096-2024
ClassificationClass II
Statuscompleted
Initiated2023-10-19
Published2023-11-15
Last updated2026-09-13 11:52 UTC
CompanyZydus Pharmaceuticals Usa
DistributionUS

Product

Oxybutynin Chloride Extended-Release Tablet USP, 5 mg, 100 count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Baddi, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. NDC # 68382-255-01

Reason

Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.

Identifiers

ndc68382-255-06
ndc68382-255-14
ndc68382-255-16
ndc68382-255-01
ndc68382-255-05
ndc68382-255-30
ndc68382-255-77
ndc68382-256-14
ndc68382-256-01
ndc68382-256-16
ndc68382-256-05
ndc68382-256-30
ndc68382-256-77
ndc68382-256-06
ndc68382-257-14
ndc68382-257-01
ndc68382-257-16
ndc68382-257-05
ndc68382-257-30
ndc68382-257-77
ndc68382-257-06
code_infoM212749, exp. date 11/2024; M214477, exp. date 11/2024; M214478, exp. date 11/2024; M214479, exp. date 11/2024; M214480, exp. date 11/2024

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: completed.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0096-2024%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.